Key result
Statin use shows no link to retear after arthroscopic rotator cuff repair.
Why the study?
The study evaluated risk factors, including hyperlipidemia and statin use, on rotator cuff healing after arthroscopic repair.
Does statin use or hyperlipidemia affect the risk of retear in patients undergoing arthroscopic rotator cuff repair?
Cohort (n=620)
Does statin use or hyperlipidemia affect the risk of retear in patients undergoing arthroscopic rotator cuff repair?
Statin use and serum lipid levels do not significantly affect the risk of retear after arthroscopic rotator cuff repair.
Answers are grounded in this paper and cite their sources.
No association between statin use and retear risk was observed; leaves open any effect on rotator cuff healing and requires prospective confirmation.
Purpose To evaluate the risk factors, including hyperlipidemia and statin use, on rotator cuff healing after arthroscopic repair. Methods A retrospective review of prospectively collected cases who underwent arthroscopic rotator cuff repair was conducted. Total cholesterol, low‐density lipoprotein, triglycerides levels, and the presence or absence of statin use and type of statins used (type 1 naturally derived statins and type 2 synthetic statins) were reviewed. Repair integrity was determined according to the Sugaya classification, assessed by magnetic resonance imaging (types 4 and 5 were considered retear). Including serum lipid levels and statin use, potential risk factors for retear were tested using multivariate logistic regression. Results Six hundred twenty cases were evaluated. The mean age was 66.9 years; 348 were male, and 272 were female. The overall retear rate was 16.1%. There was no statistically significant difference in serum lipid levels among the categories of the Sugaya classification. Multivariate logistic regression analysis showed no association between serum lipid levels and odds ratio for retear: total cholesterol (odds ratio [OR] 1.00; P = .72), low‐density lipoprotein (OR 0.99; P = .44), and triglycerides (OR 1.00; P = .88). Statins did not have a statistically significant increase or decrease in odds: type 1 statin (OR 0.3; P = .061) and type 2 statin (OR 1.4; P = .26). Older age (OR 1.1; P < .0001), male sex (OR 1.8; P = .021), and large‐to‐massive cuff tear size (OR 3.4; P < .0001) were significant risk factors. Conclusions No association was found between serum lipid levels and retear after arthroscopic rotator cuff repair. Statin use was not a statistically significant factor for retears, but different trends were seen for type 1 and type 2 statins. Older age, male sex, and large to massive tears were significant risks for retears. Level of Evidence Level III, retrospective cohort design, prognosis study.
No takes yet. Share an insight, caveat, or question.
Kotaro Yamakado (2024) conducted a cohort in Arthroscopic rotator cuff repair (n=620). Statin use (type 1 naturally derived and type 2 synthetic) vs. No statin use was evaluated on Rotator cuff retear assessed by MRI (Sugaya classification types 4 and 5) (OR 0.3 (type 1 statin), OR 1.4 (type 2 statin), p=0.061 (type 1 statin), 0.26 (type 2 statin)). Statin use was not associated with retear after arthroscopic rotator cuff repair.
Synapse has enriched 10 related papers. Consider them for comparative context: